162 related articles for article (PubMed ID: 37256122)
1. Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19.
He L; Wang C; Zhang Y; Chong H; Hu X; Li D; Xing H; He Y; Shao Y; Hong K; Ma L
Front Immunol; 2023; 14():1199938. PubMed ID: 37256122
[TBL] [Abstract][Full Text] [Related]
2. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
3. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
[TBL] [Abstract][Full Text] [Related]
4. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
[TBL] [Abstract][Full Text] [Related]
5. Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models.
Chong H; Xue J; Zhu Y; Cong Z; Chen T; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899103
[TBL] [Abstract][Full Text] [Related]
6. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Chong H; Zhu Y; Yu D; He Y
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors.
Yu X; Yuan L; Huang Y; Xu W; Fang Z; Liu S; Shao Y; Jiang S; Ma L
PLoS One; 2011 Mar; 6(3):e17605. PubMed ID: 21412427
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
Yu D; Xue J; Wei H; Cong Z; Chen T; Zhu Y; Chong H; Wei Q; Qin C; He Y
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404526
[TBL] [Abstract][Full Text] [Related]
9. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.
Zhu Y; Zhang X; Ding X; Chong H; Cui S; He J; Wang X; He Y
J Biol Chem; 2018 Apr; 293(14):5323-5334. PubMed ID: 29425101
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor.
Hu Y; Yu W; Geng X; Zhu Y; Chong H; He Y
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743078
[TBL] [Abstract][Full Text] [Related]
11. Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action.
Wang C; Cheng S; Zhang Y; Ding Y; Chong H; Xing H; Jiang S; Li X; Ma L
Viruses; 2019 Sep; 11(9):. PubMed ID: 31480738
[TBL] [Abstract][Full Text] [Related]
12. Development of potent and long-acting HIV-1 fusion inhibitors.
Chong H; Wu X; Su Y; He Y
AIDS; 2016 May; 30(8):1187-96. PubMed ID: 26919736
[TBL] [Abstract][Full Text] [Related]
13. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.
Chong H; Yao X; Zhang C; Cai L; Cui S; Wang Y; He Y
PLoS One; 2012; 7(3):e32599. PubMed ID: 22403678
[TBL] [Abstract][Full Text] [Related]
14. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques.
Chong H; Xue J; Zhu Y; Cong Z; Chen T; Wei Q; Qin C; He Y
PLoS Pathog; 2019 Feb; 15(2):e1007552. PubMed ID: 30716118
[TBL] [Abstract][Full Text] [Related]
15. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
[TBL] [Abstract][Full Text] [Related]
16. [Drug-resistance characteristics of CRF01_AE and CRF07_BC subtypes of HIV-1 strains in Sichuan province].
Yuan D; Su L; Liu H; Yu H; Yang H; Ye L; Wei D; Pei X; Liang S
Zhonghua Yu Fang Yi Xue Za Zhi; 2015 Oct; 49(10):901-6. PubMed ID: 26813724
[TBL] [Abstract][Full Text] [Related]
17. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus.
Yu D; Zhu Y; Yan H; Wu T; Chong H; He Y
Emerg Microbes Infect; 2021 Dec; 10(1):810-821. PubMed ID: 33847245
[TBL] [Abstract][Full Text] [Related]
18. The M-T hook structure is critical for design of HIV-1 fusion inhibitors.
Chong H; Yao X; Sun J; Qiu Z; Zhang M; Waltersperger S; Wang M; Cui S; He Y
J Biol Chem; 2012 Oct; 287(41):34558-68. PubMed ID: 22879603
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
20. Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus.
Leslie GJ; Wang J; Richardson MW; Haggarty BS; Hua KL; Duong J; Secreto AJ; Jordon AP; Romano J; Kumar KE; DeClercq JJ; Gregory PD; June CH; Root MJ; Riley JL; Holmes MC; Hoxie JA
PLoS Pathog; 2016 Nov; 12(11):e1005983. PubMed ID: 27855210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
